RCS - Yourgene Health PLC - Elucigene DPYD tests to be used routinely in Wales

Yourgene HealthAnnouncement

12/10/2020 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201012:nRSL7011Ba

RNS Number : 7011B  Yourgene Health PLC  12 October 2020

 

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

 

Elucigene DPYD tests to be used routinely in Wales

 

Wales is first UK nation to offer DPYD screening to patients undergoing
chemotherapy

DPYD tests screen patients to identify risk of severe side effects from
certain chemotherapy treatments

 

Manchester, UK - 12 October 2020: Yourgene (AIM: YGEN), the international
molecular diagnostics group, announces its oncology product, Elucigene DPYD
test, is now being used in Wales to routinely screen all cancer patients prior
to the start of treatment with chemotherapeutic drug 5-Fluorouracil (5-FU), to
identify the risk of severe side effects.

 

Wales is the first nation in the UK to implement this screening programme and
offer the DPYD test to all patients, with over 400 samples already taken and
6% of patients coming back positive. All Wales Medical Genomics Service
(AWMGS), which provides specialist genetic services to individuals with, or
concerned about rare genetic conditions, commenced a pilot phase earlier this
year which was successful, leading to the launch of the service this week. It
has led to all health boards across Wales routinely offering the DPYD test to
cancer patients, of which Yourgene is the sole provider.

 

Elucigene DPYD is a simple-to-use genotyping test that can identify cancer
patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency, which can
cause severe and sometimes lethal side effects in patients being treated with
chemotherapeutic drug 5-Fluorouracil (5-FU), commonly used in the treatment of
colon, oesophageal, stomach, pancreatic, breast and cervical cancers. 5-FU is
metabolized by the DPD enzyme which is encoded by the DPYD gene.

 

Yourgene will be providing the Elucigene DPYD tests to screen for
approximately 200 patients each month for the next year. If 2,400 patients are
screened, at the positive rate of 6% continues, we anticipate 144 cancer
patients will be prevented from having toxic chemotherapy reactions.

 

Lyn Rees, CEO of Yourgene, commented: "It is fantastic to see this form of
personalised medicine implemented across Wales, allowing the quality of care
for cancer patients to improve, ultimately saving lives. Yourgene is proud to
be sole supplier of DPYD so soon after its launch in September 2019 and looks
forward to similar schemes being rolled out across the UK."

 

 

 Yourgene Health plc                                                           Tel: +44 (0)161 669 8122

 Lyn Rees, Chief Executive Officer                                             investors@yourgene-health.com
 Barry Hextall, Chief Financial Officer
 Joanne Cross, Director of Marketing

 N+1 Singer (Joint Corporate Broker)                                           Tel: +44 (0)20 7496 3000
 Aubrey Powell / Tom Salvesen / George Tzimas

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)                       Tel: +44 (0)20 7710 7600
 Nicholas Moore / Matthew Blawat / Ben Maddison

 Walbrook PR Ltd (Media and Investor Relations)  Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
   Paul McManus / Lianne Cawthorne                                             Mob: 07980 541 893 / Mob: 07584 391 303

 

About Yourgene Health plc

Yourgene is an international molecular diagnostics group which develops and
commercialises genetic products and services. The group works in partnership
with global leaders in DNA technology to advance diagnostic science.

 

Yourgene develops and commercialises simple and accurate molecular diagnostic
solutions, for reproductive health and molecular genetics. The Group's
products include non-invasive prenatal tests (NIPT) for Down's Syndrome and
other genetic disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's
commercial footprint is already established in the UK, Europe, the Middle
East, Africa and Asia.

 

Our product development, research service and commercial capabilities extend
across the lifecycle of genetic test development including regulatory
submissions. Through our technical expertise and partnerships, Yourgene is
also extending its genetic testing offering into oncology.

 

Yourgene is headquartered in Manchester, UK with offices in Taipei and
Singapore, and is listed on the London Stock Exchange's AIM market under the
ticker "YGEN". For more information, visit www.yourgene-health.com
(http://www.yourgene-health.com/)  and follow us on twitter @Yourgene_Health.

 

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements.
These forward-looking statements are not historical facts but rather are based
on the Company's current expectations, estimates, and projections about its
industry; its beliefs; and assumptions. Words such as 'anticipates,'
'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject to known
and unknown risks, uncertainties, and other factors, some of which are beyond
the Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in the
forward-looking statements. The Company cautions security holders and
prospective security holders not to place undue reliance on these
forward-looking statements, which reflect the view of the Company only as of
the date of this announcement. The forward-looking statements made in this
announcement relate only to events as of the date on which the statements are
made. The Company will not undertake any obligation to release publicly any
revisions or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of this
announcement except as required by law or by any appropriate regulatory
authority.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAKENELEEFFA